REVIEW OF THE BLADDER CANCER MOLECULAR CLASSIFICATION PROPOSED: A NEW ERA – NEW TAXONOMY

Šoip Šoipi, Majda Vučić, Borislav Spajić, Božo Krušlin, Miroslav Tomić and Monika Ulamec

1Department of Urology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia; 2Ljudevit Jurak Department of Pathology and Cytology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia; 3Department of Pathology, School of Dental Medicine, University of Zagreb, Zagreb, Croatia; 4Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia

SUMMARY – The management of bladder cancer patients largely depends on pathologic staging and grading, and current morphological classification does not always show the individual patient’s risk. Despite modern surgical techniques, pre- and postoperative therapies, clinical outcomes of these patients have not changed over decades. Today, there are new biomarkers for bladder cancer showing changes in tumor biology and progression, as a result of changes in the pathways affecting cell signaling, proliferation, apoptosis, epigenetic changes, angiogenesis, and modulation of host immune response. Assessment of multiple biomarkers associated with those pathways offers new understanding of tumor behavior while identifying important panels of predicting patient management and outcomes. In this review, the most important molecules and basics of the novel molecular classification of bladder cancer are presented.

Key words: Bladder cancer; Molecular classification

Introduction

Bladder cancer is the most common malignancy involving the urinary system. Different predictive calculations evaluating cancer risk progression include tumor morphological subtype, grade and stage, presence of carcinoma in situ, vascular invasion, previous recurrence rate, tumor diameter, and number of tumors. These are important for therapy and prognosis, as well as for active patient follow up. In routine, these findings are subjective and depend on a good trained pathologist, which can largely vary in small centers where pathologist cannot subspecialize in one field. There is also the requirement of high-quality material necessary for histopathologic evaluation, as well as good sampling due to huge heterogeneity of bladder cancer.

The currently valid and still worldwide used morphological classification of urothelial cancer, according to the World Health Organization urogenital cancer classification, is loudly suggested to be replaced with new molecular taxonomy. Bladder cancer harbors chromosomal aberrations such as aneusomies, amplifications and deletions, which affect almost all chromosomes (Figs. 1 and 2). Important and intermittent genetic alterations have been identified in the TP53, FGFR3, PIK3CA and RB1 genes. Bladder cancer also frequently harbors somatic TERT promoter mutations, which occur early in the process of bladder carcinogenesis. Nevertheless, few pathways have

Correspondence to: Prof. Majda Vučić, MD, PhD, Ljudevit Jurak Department of Pathology and Cytology, Sestre milosrdnice University Hospital Centre, Vinogradska c. 29, HR-10000 Zagreb, Croatia
E-mail: majda.vucic@kbsm.hr
Received January 22, 2019, accepted April 29, 2019
Fig. 1. The most common overexpressed genes in bladder urothelial carcinoma.

Fig. 2. The most common underexpressed genes in bladder urothelial carcinoma.
been identified as the leading courses of bladder carcinogenesis and simple introduction into routine work is possible while it can be determined by the use of immunohistochemistry, which is nowadays an integral part of most pathologic laboratories².

Discussion

During the last decade, many facts have emerged in the field of genetic and epigenetic bladder carcinogenesis. Those data support the existence of two main pathways for bladder cancer, and roughly, it can be translated into non-muscle-invasive and muscle-invasive cancer¹. Most patients with newly diagnosed bladder cancer present with a non-muscle-invasive bladder cancer (NMI); they comprise up to 80% of urothelial cancer cases, include low- and high-grade papillary noninvasive and superficially invasive tumors (pTa and pT1), and they mostly reveal modifications in fibroblast growth factor receptor 3 (FGFR3), PI3-kinase catalytic subunit α (PIK3CA) and GTPase HRas (HRAS). They show mutations in the genes for chromatin-modifying enzymes (H3K27, KDM6A) as well. Those tumors usually show low mitotic and proliferation activity (low Ki-67/MIB-1 index). NMI tumors have frequent recurrences and very low mortality, with up to 20% of tumors progressing into muscle-invasive tumors (MI)¹,²,⁸.

Muscle-invasive tumors (pT2, pT3) mostly develop from flat urothelial lesions, i.e. carcinoma in situ (CIS) and may express papillary or non-papillary phenotype. They reveal p53, RB1 and gene cyclin-dependent kinase inhibitor 2A (CDKN2A) modifications and genomic instability, as well as high mitotic and

Fig. 3. High grade invasive urothelial cancer with 'basal-like' immunohistochemistry phenotype (HE, x100) (A); CK7 (x400) (B); CK5/6 (x400) (C); CD44 (x400) (D).
proliferation activity (high Ki-67/MIB-1 index). They show mutations in the genes for chromatin-modifying enzymes as well, but mostly for H3K4 and KMT2D. MI tumors are aggressive tumors with a high mortality rate.

Van Rhijn et al. describe so-called ‘molecular grade’ for NMI tumors, a prognostic variable based on FGFR3 mutation status and proliferation index due to favorable outcome of tumors with FGFR3 overexpression. Mutated FGFR3 activates RAS pathway, but a small percentage of NMI bladder cancers harbor RAS mutation without FGFR mutation.

One of the first prognostic markers important in the prognosis of MI and NMI tumors was TP53, which is mutated in most of the MI bladder cancers and can coexist with RB1 inactivation.

The PIK3/AKT/MTOR pathway mutations are described in the subset of MI cancers, and epigenetic alterations were found to be good predictive markers for progression and survival.

Gene expression profiling showed different molecular pathways, as well as genetic mutations and epigenetic modifications at a high extent, and according to different groups of authors, it is shown that urothelial carcinoma may be divided into two major molecular groups using simple immunohistochemistry staining, luminal and basal.

Basal types (or squamous-like subgroup) (Fig. 3) show p63, CK5/6, EGFR and CD44 expression and are negative for CK20 immunostaining (expression of basal markers and downregulation of urothelial differentiation markers; KRT5/6+ KRT14+ FOXA1- GATA3- phenotype). This group is associated with worse prognosis but better response to neoadjuvant chemotherapy. The third of the MI and a small subset of NMI bladder cancers are classified in the basal subtype group. Luminal type is related to FGFR3 mutation and expression of estrogen receptor, ERBB2 and PPARy. It can be divided in two subgroups: urothelial-like, with urothelial differentiation, harboring alterations in the FGFR3-pathway; most of the NMI bladder tumors are part of this group. Second is the luminal subtype: genomic unstable/infiltrated/p53-like has expression of urothelial differentiation markers but not related to the FGFR3-pathway and is found to be sensitive to PD-L1 inhibitor therapy and resistant to neoadjuvant therapy. A type (claudin low) which is described in relation to epithelial-mesenchymal transition (EMT) with rich lymphocytic reaction, as well as a neuronal subtype expressing neuroendocrine genes and mutation of TP53 and RB-1 are described in MI bladder cancer and comprise a small subset of these tumors. In some types, the immune-related subgroups were described, with high expression of immune genes and variable expression of EMT genes.

Some of the subtypes described are related to characteristic morphological and immunohistochemical phenotype, although additional studies are required.

Due to the huge mutation burden and heterogeneity of bladder cancer, therapy of MI tumors has remained the same for decades; platinum-based combination chemotherapy is the first-line treatment for patients with metastatic MI urothelial cancer. In the previously described molecular classification, the basal-like subtype is a candidate for neoadjuvant chemotherapy. For long time, second-line therapy was not standardized and in recent years several agents and strategies, immune checkpoint inhibitors targeting PD-1/PDL-1 have been developed and showed significant therapeutic response in metastatic urothelial cancer.

Conclusion

Increasing knowledge on cancer genomics is changing the diagnostic and therapeutic approach to genitourinary (GU) cancers. Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with GU cancers at different stages of the disease. Current knowledge about genomic GU cancer supports creating patient groups for targeted therapies. Robust and reliable biomarkers are crucial in this process, but recent insights indicate that a single biomarker for patient selection may not be feasible, given that tumor progression, as well as immune responses are dynamic processes and evolve over time.

Patients need unique treatment and controlled modalities, however, histopathologic finding determined by morphological features is still necessary for clinical intervention and therapy decisions. Molecular classification shows some overlap with pathologic grade and stage, and the molecular taxonomy proposed is related to different treatment possibilities, but additional studies are needed to propose definitive classification criteria.
Acknowledgment

This review was supported by the European Union through the European regional development fund.

References

1. Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO Classification of Tumours of the Urinary System and Male Genital Organs. WHO/IARC Classification of Tumours, 4th Edition, Volume 8, Lyon, 2016.

2. Sjödahl G, Lövgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, et al. Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol. 2013;183:681-91. doi: 10.1016/j.ajpath.2013.05.013.

3. Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horiwich A, ESMO Guidelines Working Group Bladder Cancer. ESMO Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:3. doi: 10.1093/annonc/mdu223.

4. Ružić, B, Katušić J, Spajić B, Reljić A, Popović A, Štimac G, et al. History of urology at the Sestre milosrdnice University Hospital Center. Acta Clin Croat. 2018 (1);57:9-20. doi: 10.20471/acc.2018.57.s1.01.

5. Soloway M, Khoury S, editors. Bladder Cancer: 2nd International Consultation on Bladder Cancer. International Consultation on Urologic Diseases, 2nd edition. Vienna, 2012.

6. Bass BP, Enge IKB, Greytak SR, Moore HM. A review of pre-analytical factors affecting molecular, protein and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? Arch Pathol Lab Med. 2014;138(11):1520-30. doi: 10.5858/arpa.2013-0691-RA.

7. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Rodriguez IP, Chakravarthi BVS, Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649-58. doi: 10.1016/j.neo.2017.05.002.

8. Eich ML, Dysrøsjøt L, Netto GJ. Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. Virchows Arch. 2017;471(2):271-80. doi: 10.1007/s00428-017-2119-x.

9. van Rhijn BWG, Zuiverloon TCM, Vis AN, Radvanyi F, van Leenders GJLH, Ooms BCM, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle invasive bladder cancer. Eur Urol. 2010;58:433-41. doi: 10.1016/j.eururo.2010.05.043.

10. Gevaert T, Montironi R, Lopez-Beltran A, van Leenders G, Allory Y, De Ridder D. Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. Semin Cancer Biol. 2018;52:216-27. doi: 10.1016/j.semcancer.2017.10.004.

11. Netto GJ, Tafe LJ. Emerging bladder cancer biomarkers and targets of therapy. Urol Clin North Am. 2016;43:63-72. doi: 10.1016/j.ucl.2015.08.006.

12. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315-22. doi: 10.1038/nature12965.

13. Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014;11:400-10. doi: 10.1038/nruro.2014.129.

14. Aine M, Eriksson P, Liedberg F, Sjödahl G, Höglund M. Biological determinants of bladder cancer gene expression subtypes. Sci Rep. 2015;5:1095-7. doi: 10.1038/srep10957.

15. Kim J, Akbani R, Creighton CJ, Lerner SP, Weinstein JN, Getz G, Kwiatkowski DJ. Invasive bladder cancer: genomic insights and therapeutic promise. Clin Cancer Res. 2015;21:4514-24. doi: 10.1158/1078-0432.CCR-14-1215.

16. Kardos J, Chai S, Mose LE, Selitsky SR, Krishnan B, Saito R, et al. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight. 2016;17(1);e85902. doi: 10.1172/jci.insight.85902.

17. Lernera SP, McConkey MB, Hoadleye KA, Chand KS, Kime WY, Radvanyi F, et al. Bladder cancer molecular taxonomy: summary from a Consensus Meeting. Bladder Cancer. 2016;2:37-47. doi: 10.3233/BLC-150037.

18. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res. 2007;13:2046-53. doi: 10.1158/1078-0432.CCR-06-2476.
Sažetak

PREGLED NOVOPREDLOŽENE MOLEKULARNE KLASIFIKACIJE KARCINOMA MOKRAĆNOG MJEHURA: NOVA ERA – NOVA TAKSONOMIJA

Š. Šoipi, M. Vučić, B. Spajić, B. Krušlin, M. Tomic i M. Ulamec

Liječenje karcinoma mokraćnog mjehura uvelike ovisi o patohistološkom tipu, gradusu i stadiju tumora, a današnja morfološka klasifikacija ne može u potpunosti odrediti individualne potrebe i procjenu rizika za pojedinačne bolesnike. Unatoč modernim kirurškim tehnikama i novijim terapijskim mogućnostima klinički ishod bolesnika s tumorom mokraćnog mjehura u posljednjih nekoliko desetljeća nije se promijenio. Danas su poznati brojni biološki biljezi koji se odnose na karcinom mokraćnog mjehura, a pokazuju promjene u biologiji i progresiji tumora te su rezultat različitih promjena u signalnim putovima stanice, proliferaciji, apoptozi, epigenetskim promjenama, angiogenezi ili modulaciji imunog odgovora domaćina. Procjena više bioloških biljega povezanih s navedenim putovima omogućuje prikaz ponašanja tumora, jer identificira važne panele predviđanja terapije i ishoda. U ovom prikazu stavlja se naglasak na najvažnije molekule koje čine osnovu novopredložene molekularne klasifikacije karcinoma mokraćnog mjehura

Ključne riječi: Karcinom mokraćnog mjehura; Molekularna klasifikacija